Method for treating psoriasis
Methods and compositions are provided for the creation and screening of non-human animal models having many of the histologic characteristics of human psoriasis. Immunocompromised host animals are injected with a purified population of CD45Rb positive cells, which are tolerant of the host major histocompatibility antigens, but are mismatched at one or more minor antigens. The injected cells are stimulated with a pro-inflammatory cytokine, e.g. IL-12, and a polyclonal activating agent. The injected animals develop a chronic skin disorder that includes histological features observed in human psoriasis, e.g. rete pegs, severe acanthosis and infiltration of Th1 cells into the dermis.
1. A method of treating a patient suffering from psoriasis comprising the step of administering to the patient a therapeutically effective amount of an antibody that binds to interleukin 12 (IL-12).
2. A method for treating a patient suffering from psoriasis consisting of administering to the patient an effective amount of a therapeutically active agent consisting essentially of an antibody that binds interleukin 12.
3. The method according to claim 2 , wherein said antibody is a monoclonal antibody.
4. The method according to claim 2 , wherein said antibody neutralizes interleukin 12.
5. The method according to claim 2 , wherein said antibody is administered orally, topically, or parenterally.
6. The method according to claim 2 , wherein said antibody is administered subcutaneously, intramuscularly, or intravascularly.
7. A method of treating a patient suffering from psoriasis comprising the step of administering to the patient a therapeutically effective amount of an antibody that binds to interleukin 12, wherein said antibody neutralizes interleukin 12.